Indivior PLC (LON: INDV) have seen their shares dip on Monday afternoon, despite reports that the firm had made progress in its Sublocade Injection analysis.
Indivior is a global pharmaceutical company working to working to help change patients’ lives by pioneering life-transforming treatment for addiction and other serious mental illnesses.
The FTSE250 (INDEXFTSE: MCX) listed pharmaceutical firm manufactures and markets medicines for the treatment of moderate to severe opioid use disorder with a global portfolio in over 40 countries.
In a report on Monday, the firm said that new analysis from a year long investigation of monthly Sublocade injection showed either improved or stable patient-centred outcomes versus placebo.
However, shareholders did not seem so keen on the announcement as shares dipped following the update.
Shares of Indivior dipped 4.46% to 38p. 2/12/19 13:11BST.
Indivior have seen a turbulent time in financial 2019, after the firm reported a slump in third quarter profit on October 31.
Additionally, the firm released a new treatment in February however shares fell following issues over copyright issues following issues with rival Dr. Reddy’s Laboratories (NSE:DRREDDY).
Today, the firm gave an update which did not seem to spark shareholder appetite.
Sublocade injection is intended to treat patients with opioid use disorder who have already taken a medication containing active ingredient buprenorphine. The 12-month study looked at a number of outcome measures, including treatment effectiveness and improvement in the severity of addition as measured by a patient reported Addiction Severity Index.
Other measures included health and employment status, use of healthcare resources, and medication satisfaction. Study participants who were treated with Sublocade injection showed improved or maintained outcomes across these measures when compared to a placebo.
Christian Heidbreder, Indivior’s chief scientific officer, said: “These 12-month findings strengthen our original observations that previously showed that participants receiving Sublocade over a 6-month period reported better health, higher medication satisfaction, increased employment, and decreased healthcare utilization compared to placebo.
“These findings also show that patient-centred outcomes that can be measured during office visits may help clinicians assess their patient’s improvement.”
In the pharmaceuticals market, updates have come from Faron Pharmaceuticals ImmuPharma (LON: IMM) who have seen their shares rise after progress in their respective updates.